AZNAstraZenecaSigning up patients
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 152 (planned)
- Started
- Nov 24, 2025
- Main results expected
- Feb 23, 2029
- Fully finished
- Feb 23, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over: Approximately 46 months
Part A: Number of partcipants with dose limiting toxicity (DLT)
Measured over: Approximately 46 months
Part B: Objective response (OR)
Measured over: Approximately 46 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06996782 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC